ORLANDO—In new research the Stanford V chemotherapy regimen for Hodgkin’s Disease was inferior to ABVD because it required “obligate radiotherapy” — according to George Canellos of the Dana-Farber Cancer Institute in Boston — who gives eCancerRadio his opinion of two papers presented at the American Society of Hematology annual meeting (December 3-7, 2010) held in Orlando: one from California comparing the two regimens in patients with stage I/II bulky mediastinal Hodgkin Lymphoma; the second from Illinois in which the same comparison was made in patients who had locally extensive and advanced stage disease.
ASH TELEVISION NEWS REPORTS:
For full coverage of the American Society of Hematology’s 2010 Orlando meeting, visit www.eCancerMedicalScience.com for eCancerTV
LISTEN
[audio:https://www.audiomedica.com/podcasting/ecancer/101210GeorgeCanellos415n6PODCASTLoRes.mp3]
